Regeneron agrees to collaborate with ModeX for a $1B+ antibody R&D

Regeneron is partnering with ModeX Therapeutics to develop multispecific antibodies, offering $7M upfront and over $1B in potential milestone payments.

Why it matters: The deal could fast-track next-gen treatments in cancer, immunology, and metabolic diseases by combining ModeX’s multispecific antibody platform with Regeneron’s development power.

Backstory: ModeX uses its MSTAR platform to design antibodies that target multiple disease pathways. Along with Regeneron, ModeX partners with Merck and previously received $200M+ from BARDA for COVID-19 work.

Zoom in: ModeX could earn $200M+ per antibody advanced. Regeneron is responsible for all development and commercialization for selected candidates. ModeX’s first trispecific antibody just entered phase 1/2 trials for advanced tumors.

Big picture: This move aligns with a growing industry push toward complex, multi-targeted biologics that can tackle hard-to-treat diseases more effectively than traditional therapies.